OSE Immunotherapeutics SA (OSE) Stock Statistics & Valuation Metrics

OSE Immunotherapeutics SA has a market cap or net worth of €161.50M. The enterprise value is €144.00M.

OSE Immunotherapeutics SA has 22,463,263 shares outstanding. The number of shares has decreased by -2.65% in one year.

OSE Immunotherapeutics SA’s return on equity (ROE) is 0.59 and return on invested capital (ROIC) is 36.67%.

The current PE Ratio of OSE Immunotherapeutics SA is 4.2. OSE Immunotherapeutics SA’s PEG ratio is -0.02.

In the last 12 months, OSE Immunotherapeutics SA had revenue of 69.88M and earned 37.45M in profits. Earnings per share was 1.72.

In the last 12 months, operating cash flow was 48.44M and capital expenditures -77.00K, giving a free cash flow of 48.36M billion.

OSE Immunotherapeutics SA pays an annual dividend of ―, resulting in a dividend yield of ―

OSE Immunotherapeutics SA upcoming earnings date is Sep 25, 2025, During Market Hours (Confirmed).

OSE Immunotherapeutics SA as a current ratio of 3.46, with Debt / Equity ratio of 72.29%

In the past 12 months, OSE Immunotherapeutics SA has paid 2.39M in taxes.

OSE Immunotherapeutics SA EV to EBITDA ratio is 4.51, with an EV/FCF ratio of 3.84.

OSE Immunotherapeutics SA has €16.75M in cash and marketable securities with €46.13M in debt, giving a net cash position of -€29.39M billion.

Gross margin is 83.82%, with operating margin of 62.59%, and net profit margin of 53.59%.

The average price target for OSE Immunotherapeutics SA is €10.25, which is 11.43% higher than the current price. The consensus rating is Moderate Buy